Browse the evidence

Use of GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, dulaglutide) for weight loss is associated with an emerging adverse effect of alopecia, primarily presenting as telogen effluvium or androgenetic alopecia.

If you are using a GLP-1 medication for weight loss and notice increased hair shedding, do not immediately stop the medication. This is a reported side effect, often presenting as temporary shedding (telogen effluvium) linked to metabolic stress or rapid weight loss. Consult a dermatologist to confirm the type of hair loss; it may be manageable without discontinuing your weight loss treatment.

MBS is associated with a higher risk of divorce or separation compared to the general population, particularly within the first five years post-surgery.

Be aware that your relationship dynamics may change significantly after surgery. While many relationships improve, there is a statistically higher risk of separation. Proactive communication and counseling can help navigate these changes.

Obesity is a disease of the ponderostat characterized by a dysregulated neuroendocrine set point that actively defends a higher body weight through compensatory reductions in energy expenditure and increases in appetite.

Recognize that obesity involves a biological set point that resists change. Simple calorie counting often fails because the body compensates by lowering metabolism and increasing hunger. Effective management may require addressing these biological drivers, potentially through pharmacological treatments that target the ponderostat, rather than relying solely on willpower.

Use of GLP-1 receptor agonists (GLP-1RAs) is associated with a significantly increased risk of developing alopecia, specifically androgenetic alopecia (AGA), across multiple agents including semaglutide, tirzepatide, dulaglutide, liraglutide, and exenatide.

If you are using a GLP-1RA (like semaglutide or tirzepatide), be aware that there is a statistically significant, though small, increased risk of hair thinning (androgenetic alopecia). This risk varies by drug; tirzepatide did not show this risk in this study, while semaglutide, dulaglutide, and liraglutide did. The risk is not universal, and it does not appear to affect Alopecia Areata. Discuss this with your provider, especially if you have a family history of hair loss, as the mechanism may be related to metabolic changes or rapid weight loss rather than the drug itself.

Tirzepatide use is associated with a very low absolute risk of acute pancreatitis (<1%), and when cases occur, they are typically mild and confounded by traditional etiologies such as gallstones or alcohol.

If you are taking tirzepatide, be aware that pancreatitis is a known but rare side effect (<1% risk). Most cases are mild and often linked to other factors like gallstones. Report severe abdominal pain to your doctor immediately, but do not let fear of this rare event prevent you from using a medication that effectively manages weight and blood sugar.

Tirzepatide, a dual GLP-1/GIP agonist, demonstrates significant neuroprotective effects against neurodegenerative diseases (Alzheimer's, Parkinson's) and cerebrovascular events, outperforming semaglutide due to its dual-action mechanism.

If you have Type 2 Diabetes or Obesity, discuss with your doctor whether GLP-1/GIP agonists like Tirzepatide might offer neuroprotective benefits beyond weight loss, especially if you have a family history of dementia or cognitive decline. Tirzepatide may be superior to Semaglutide for brain health due to its dual mechanism.

An altered enteric microbiome contributes to obesity by enhancing energy harvest from dietary roughage, modulating intestinal physiology to slow transit, and influencing the entero-insular axis and central nervous system to increase appetite and fat storage.

Your gut bacteria play a significant role in how much energy you get from food and how your body stores it. While diet and exercise remain important, understanding that your microbiome influences hunger, fat storage, and nutrient absorption can help explain why weight management is challenging. Strategies like targeted probiotics or dietary changes that support a healthy microbiome may offer additional support alongside traditional lifestyle changes.

Perioperative use of GLP-1 receptor agonists in obese patients undergoing total hip arthroplasty significantly reduces the incidence of periprosthetic joint infection and 90-day hospital readmissions.

If you are obese and scheduled for hip replacement, ask your surgeon about continuing or starting GLP-1 agonists (like semaglutide) up to 3 months before surgery. This may lower your risk of infection and hospital readmission without increasing other complications.

Tirzepatide does not demonstrate a disproportionate risk of gynecological hemorrhagic events compared to semaglutide in real-world post-marketing surveillance.

If you are using tirzepatide and experience menstrual changes, know that current large-scale data shows your risk of bleeding is statistically similar to those using semaglutide. High consumer reporting on social media may inflate the perception of risk, but clinical evidence does not support a unique safety signal for tirzepatide regarding gynecological hemorrhage.

Off-label use of semaglutide (Ozempic) for aesthetic weight loss in non-diabetic individuals causes therapeutic exclusion for Type 2 Diabetes patients due to supply shortages.

If you are using Ozempic off-label, be aware that your demand contributes to shortages for diabetics. Consider using approved alternatives like Wegovy if available, or prioritize lifestyle changes to reduce pressure on the supply chain for those who medically need it.

Rapid weight loss induced by semaglutide causes 'Ozempic Face' and 'Ozempic Butt' due to the skin's inability to shrink at the same rate as fat loss.

If you are using semaglutide, expect potential skin laxity, especially in the face and buttocks. Slower weight loss allows skin to adapt; rapid loss may result in sagging. Consider consulting a dermatologist for skin-tightening options if this is a major concern.

Discontinuation of semaglutide leads to significant weight regain (rebound effect) and psychological distress due to the dissipation of hormonal effects.

If you stop semaglutide, expect significant weight regain and increased hunger. Plan for a gradual taper and lifestyle changes to maintain weight. Psychological support may be needed to manage the rebound effect.

Neutralization of the chemokine CXCL10 prevents high-fat diet-induced skeletal muscle atrophy and inflammation in mice.

This research suggests that in states of high metabolic stress (like high-fat diets), muscle loss is driven by specific inflammatory signals (CXCL10). While this is a mouse study, it implies that managing systemic inflammation might be as important as exercise for preserving muscle mass during weight loss or obesity.

Unimolecular GLP-1/Apelin hybrid peptides (specifically ELA, ELA-Lys12, and ELA-Lys38) cause prominent appetite suppression in mice without inducing malaise, with effects lasting up to 42 hours for the base peptide and 63 hours for acylated forms.

This research suggests that combining GLP-1 and Apelin pathways in a single peptide molecule can effectively reduce food intake for extended periods (up to 63 hours with acylation) without causing the nausea often seen with current GLP-1 drugs. While promising in mice, this is pre-clinical data and not yet a human treatment option.

GLP-1/Apelin hybrid peptides (ELA, ELA-Lys12, ELA-Lys38) significantly improve glucose tolerance and insulin secretion in both lean and high-fat-fed mice, with effects lasting up to 21 hours for acylated forms.

These hybrid peptides effectively lower blood glucose levels in mice for up to 21 hours, outperforming single-target approaches in duration. This suggests potential for less frequent dosing in diabetes management, though human trials are required.

GLP-1/Apelin hybrid peptides enhance beta-cell proliferation and protect against cytokine-induced apoptosis, contributing to beta-cell survival.

These hybrid peptides show promise in protecting beta-cells from stress and promoting their growth in laboratory settings. This could translate to better long-term diabetes management by preserving the body's natural insulin production capacity.

GIP receptor (GIPR) agonism suppresses inflammation-induced conditioned taste avoidance (aversion) by attenuating the activity of parabrachial CGRP neurons, while simultaneously enhancing inflammation-induced anorexia via distinct dorsal vagal complex (DVC) circuits.

If you are experiencing sickness-induced nausea and loss of appetite, standard anti-nausea drugs might not stop the feeling of aversion, and standard anti-inflammatories might not stop the nausea. This research suggests that GIP-based therapies could specifically target the 'sickness feeling' (aversion) via brain circuits, potentially allowing patients to feel better without necessarily worsening their lack of appetite, though it does increase food suppression. This is currently experimental in mice.

Tirzepatide use is associated with a significantly increased risk of gastrointestinal adverse events (GIAEs), with nausea and diarrhea being the most frequent, and eructation and impaired gastric emptying showing the highest disproportionality.

If you start tirzepatide, expect gastrointestinal side effects like nausea or diarrhea, especially in the first few months. The risk is higher if you are male, over 65, have Type 2 Diabetes, or take other medications. Working with your doctor to start with a low dose and increase it slowly can help your body adjust and reduce these side effects.

Gut microbiota dysbiosis in obesity drives hypertension through intestinal barrier dysfunction, allowing lipopolysaccharide (LPS) translocation that triggers systemic inflammation and vascular damage.

Your gut health may be contributing to your high blood pressure. While medication is important, focusing on a diet that supports a diverse microbiome (high fiber, fermented foods) and managing weight can help restore gut barrier integrity and reduce inflammation, potentially lowering blood pressure.

Short-chain fatty acids (SCFAs) produced by gut bacteria have complex effects: while generally beneficial for blood pressure regulation via GPCR activation, increased production in obesity may contribute to calorie harvest and weight gain.

Fiber is good for your heart, but if you are struggling with weight, be aware that your gut bacteria might be extracting more calories from your food. Focus on a balanced diet rather than just maximizing fiber intake if weight loss is a primary goal.

Online marketing of GLP-1 receptor agonists as 'weight loss injections' creates unrealistic expectations and encourages off-label, non-medical use, posing significant public health risks.

Be skeptical of online content that promotes GLP-1 injections as 'weight loss injections' without mentioning medical indications, side effects, or the need for a prescription. These are serious medications for obesity management, not cosmetic shortcuts. Consult a healthcare provider to determine if you are a suitable candidate and to understand the risks and benefits.

Activation of the mitochondrial unfolded protein response (UPRmt) in adipocytes serves as a critical adaptive mechanism to restore mitochondrial proteostasis and mitigate dysfunction during metabolic stress, offering a potential therapeutic strategy for obesity and related metabolic disorders.

This paper highlights that your body has a sophisticated internal repair system (UPRmt) that activates when mitochondria are stressed. While there is no specific 'dose' provided, the text suggests that factors like cold exposure, exercise, and specific hormonal signals can induce 'browning' of white fat and activate these pathways. To support this mechanism, focus on activities known to stimulate mitochondrial biogenesis and stress adaptation, such as regular physical exercise and potentially cold exposure, as these are linked to the activation of UPRmt and improved metabolic health in the reviewed literature.

Greater lean body mass loss with tirzepatide is mechanistically linked to its dual GLP-1/GIP receptor agonism, as GIP receptors are broadly expressed in immune, stromal, and vascular muscle compartments, unlike the more restricted GLP-1 receptor.

Tirzepatide's unique ability to activate GIP receptors may affect muscle tissue differently than semaglutide by influencing immune and vascular cells in muscle, potentially contributing to greater muscle loss.

Improvement in cellulite severity is not significantly correlated with changes in body weight or fat mass, indicating that local structural and metabolic-dermal interventions are primary drivers of cellulite reduction rather than systemic adiposity loss.

If you are trying to reduce cellulite, relying solely on weight loss or fat loss may not yield visible improvements in skin texture. This study suggests that combining systemic metabolic health (e.g., managing insulin/inflammation) with targeted local treatments (like specific topical formulations) is more effective for cellulite than weight loss alone. Focus on local tissue health and metabolic balance rather than just the scale.